This page contains a Flash digital edition of a book.
Barnett_Cardiology_book_temp 22/12/2009 10:42 Page 62
Diabetes Management Incretin Mimetics
promotes satiety and suppresses energy intake in humans, (exendin-4) on glycemic control and weight over 30 weeks 40. Moretto TJ, Milton DR, Ridge TD, et al., Efficacy and
J Clin Invest, 1998;101:515–20. in metformin-treated patients with type 2 diabetes, Diabetes tolerability of exenatide monotherapy over 24 weeks in
8. Gutzwiller JP, Tschopp S, Bock A, et al., Glucagon-like peptide Care, 2005;28:1092–1100. antidiabetic drug-naive patients with type 2 diabetes: a
1 induces natriuresis in healthy subjects and in insulin- 27. Buse JB, Henry RR, Han J, et al.; Exenatide-113 Clinical Study randomized, double-blind, placebo-controlled, parallel-group
resistant obese men, J Clin Endocrinol Metab, 2004;89:3055–61. Group, Effects of exenatide (exendin-4) on glycemic control study, Clin Ther, 2008;30:1448–60.
9. Nyström T, The potential beneficial role of glucagon-like over 30 weeks in sulfonylurea-treated patients with type 2 41. Fineman MS, Shen LZ, Taylor K, et al., Effectiveness of
peptide-1 in endothelial dysfunction and heart failure diabetes, Diabetes Care, 2004;27:2628–35. progressive dose-escalation of exenatide (exendin-4) in
associated with insulin resistance, Horm Metab Res, 2008;40: 28. Kendall DM, Riddle MC, Rosenstock J, et al., Effects of reducing dose-limiting side effects in subjects with type 2
593–606. exenatide (exendin-4) on glycemic control over 30 weeks in diabetes, Diabetes Metab Res Rev, 2004;20:411–17.
10. Bose AK, Mocanu MM, Carr RD, et al., Glucagon-like peptide patients with type 2 diabetes treated with metformin and a 42. Irie S, Matsumura Y, Zdravkovic M, et al., Tolerability,
1 can directly protect the heart against ischemia/ sulfonylurea, Diabetes Care, 2005;28:1083–91. pharmacokinetics and pharmacodynamics of the once-
reperfusion injury, Diabetes, 2005;54:146–51. 29. Barnett AH, Burger J, Johns D, et al., Tolerability and efficacy daily human GLP-1 analog liraglutide in Japanese healthy
11. Nikolaidis LA, Mankad S, Sokos GG, et al., Effects of of exenatide and titrated insulin glargine in adult patients subjects: a randomized, double-blind, placebo-controlled
glucagon-like peptide-1 in patients with acute myocardial with type 2 diabetes previously uncontrolled with metformin dose-escalation study, Int J Clin Pharmacol Ther, 2008;46:
infarction and left ventricular dysfunction after successful or a sulfonylurea: a multinational, randomized, open-label, 273–9.
reperfusion, Circulation, 2004;109:962–5. two-period, crossover noninferiority trial, Clin Ther, 2007;29: 43. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes
12. Vilsbøll T, Brock B, Perrild H, et al., Liraglutide, a once-daily 2333–48. Association; European Association for Study of Diabetes,
human GLP-1 analogue, improves pancreatic B-cell function 30. Heine RJ, Van Gaal LF, Johns D, et al.; GWAA Study Group, Medical management of hyperglycemia in type 2 diabetes: a
and arginine-stimulated insulin secretion during Exenatide versus insulin glargine in patients with consensus algorithm for the initiation and adjustment of
hyperglycaemia in patients with type 2 diabetes mellitus, suboptimally controlled type 2 diabetes: a randomized trial, therapy: a consensus statement of the American Diabetes
Diabet Med, 2008;25:152–6. Ann Intern Med, 2005;143:559–69. Association and the European Association for the Study of
13. Drucker DJ, Nauck MA, The incretin system: glucagon-like 31. Nauck MA, Duran S, Kim D, et al., A comparison of twice- Diabetes, Diabetes Care, 2009;32:193–203.
peptide-1 receptor agonists and dipeptidyl peptidase-4 daily exenatide and biphasic insulin aspart in patients with 44. Sitagliptin (JANUVIA®), US SPC (2008), Merck & Co Inc,
inhibitors in type 2 diabetes, Lancet, 2006;368(9548): type 2 diabetes who were suboptimally controlled with Whitehouse Station, NJ 08889, US.
1696–1705. sulfonylurea and metformin: a non-inferiority study, 45. Herman GA, Stevens C, Van Dyck K, et al., Pharmacokinetics
14. Mentlein R, Dipeptidyl-peptidase IV (CD26) – role in the Diabetologia, 2007;50:59–67. and pharmacodynamics of sitagliptin, an inhibitor of
inactivation of regulatory peptides, Regul Pept, 1999;85:9–24. 32. Amori RE, Lau J, Pittas AG, Efficacy and safety of incretin dipeptidyl peptidase IV, in healthy subjects: results from
15. Exenatide (BYETTA®), US SPC (2008), Amylin therapy in type 2 diabetes: systematic review and meta- two randomized, double-blind, placebo-controlled
Pharmaceuticals Inc, San Diego, CA, USA and Eli Lilly and analysis, JAMA, 2007;298:194–206. studies with single oral doses, Clin Pharmacol Ther, 2005;78:
Company, Indianapolis, IN, US. 33. Buse JB, Klonoff DC, Nielsen LL, et al., Metabolic effects of 675–88.
16. Gryskiewicz KA, Coleman CI, Focus on exenatide. A novel two years of exenatide treatment on diabetes, obesity, and 46. Herman GA, Bergman A, Liu F, et al., Pharmacokinetics and
incretin mimetic hormone for the treatment of type 2 hepatic biomarkers in patients with type 2 diabetes: an pharmacodynamic effects of the oral DPP-4 inhibitor
diabetes, Formulary, 2005;40:86–90. interim analysis of data from the open-label, uncontrolled sitagliptin in middle-aged obese subjects, J Clin Pharmacol,
17. Exenatide (BYETTA®), EU SPC (2009), Eli Lilly Nederland BV, extension of three double-blind, placebo-controlled trials, 2006;46:876–86.
Houten, The Netherlands. Clin Ther, 2007;29:139–53. 47. Bergman AJ, Stevens C, Zhou Y, et al., Pharmacokinetic and
18. Kolterman O, Kim DD, Shen L, et al., Pharmacokinetics, 34. Marre M, Shaw J, Brändle M, et al., Liraglutide, a once-daily pharmacodynamic properties of multiple oral doses of
pharmacodynamics, and safety of exenatide in patients with human GLP-1 analogue, added to a sulphonylurea over 26 sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind,
type 2 diabetes mellitus, Am J Health Syst Pharm, 2005;62: produces greater improvements in glycaemic and weight randomized, placebo-controlled study in healthy male
173–81. control compared with adding rosiglitazone or placebo in volunteers, Clin Ther, 2006;28:55–72.
19. Madsbad S, Treatment of type 2 diabetes with incretin-based subjects with type 2 diabetes (LEAD-1 SU), Diabetic Medicine, 48. Goldstein BJ, Feinglos MN, Lunceford JK, et al.; Sitagliptin 036
therapies, Lancet, 2008;373:438–9. 2009;26:268–78. Study Group, Effect of initial combination therapy with
20. Kim D, MacConell L, Zhuang D, et al., Effects of once-weekly 35. Nauck MA, Frid A, Hermansen K, et al., Efficacy and safety sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin
dosing of a long-acting release formulation of exenatide on comparison of liraglutide, glimepiride, and placebo, all in on glycemic control in patients with type 2 diabetes, Diabetes
glucose control and body weight in subjects with type 2 combination with metformin in type 2 diabetes, Diabetes Care, Care, 2007;30:1979–87.
diabetes, Diabetes Care, 2007;30:1487–93. 2009;32:84–90. 49. Riche DM, East HE, Riche KD, Impact of sitagliptin on
21. Drucker DJ, Buse JB, Taylor K, et al., for the DURATION-1 36. Garber A, Henry R, Ratner R, et al., Liraglutide versus markers of beta-cell function: a meta-analysis, Am J Med Sci,
Study Group, Exenatide once weekly versus twice daily for glimepiride monotherapy for type 2 diabetes (LEAD-3 2009;337:321–8.
the treatment of type 2 diabetes: a randomised, open-label, Mono): randomised, 52-week, phase III, double-blind, 50. Rosenstock J, Aguilar-Salinas C, Klein E, et al.; for the CV181-
non-inferiority study, Lancet, 2008;372:1240–50. parallel-treatment trial, Lancet, 2009;373:473–81. 011 Study Investigators, Effect of saxagliptin monotherapy in
22. Liraglutide (VICTOZA®), EU SPC (2009), Novo Nordisk A/S, 37. Zinman B, Gerich J, Buse J, et al., Efficacy and safety of the treatment-naïve patients with type 2 diabetes, Curr Med Res
Bagsværd, Denmark. human GLP-1 analog liraglutide in combination with Opin, 2009;25:2401–11.
23. Steensgaard DB, Thomsen JK, Olsen HB, et al., The molecular metformin and TZD in patients with type 2 diabetes mellitus 51. Chacra AR, Tan GH, Apanovitch A, et al., Saxagliptin added to
basis for the delayed absorption of the once-daily human (LEAD-4 Met+TZD), Diabetes Care, 2009;32:1224–30. a submaximal dose of sulphonylurea improves glycaemic
GLP-1 analoge, liraglutide, Diabetes, 2008;57(Suppl. 1):A164 38. Russell-Jones D, Vaag A, Schmitz O, et al., on behalf of the control compared with uptitration of sulphonylurea in
(552–P). LEAD-5 (Liraglutide Effect and Action in Diabetes 5) met+SU patients with type 2 diabetes: a randomised controlled trial,
24. Elbrønd B, Jakobsen G, Larsen S, et al., Pharmacokinetics, Study Group, Liraglutide vs insulin glargine and placebo in Int J Clin Pract, 2009;63:1395–1406.
pharmacodynamics, safety, and tolerability of a single-dose combination with metformin and sulphonylurea therapy in 52. Defronzo RA, Hissa MN, Garber AJ, et al.; for the Saxagliptin
of NN2211, a long-acting glucagon-like peptide 1 derivative, type 2 diabetes mellitus: a randomised controlled trial 014 Study Group, The efficacy and safety of saxagliptin
in healthy male subjects, Diabetes Care, 2002;25:1398–1404. (LEAD-5 met+SU), Diabetologia, 2009;52:2046–55. when added to metformin therapy in patients with
25. Agersø H, Jensen LB, Elbrond B, et al., The 39. Buse J, Rosenstock J, Sesti G, et al., for the LEAD 6 study inadequately controlled type 2 diabetes on metformin alone,
pharmacokinetics, pharmacodynamics, safety and group, Liraglutide once a day versus exenatide twice a day Diabetes Care, 2009;32:1649–55.
tolerability of NN2211, a new long-acting GLP1 derivative, in for type 2 diabetes: a 26-week randomised, parallel-group, 53. Saxagliptin (ONGLYZA®), US SPC (2009), Bristol-Myers
healthy men, Diabetologia, 2002;45:195–202. multinational, open-label trial (LEAD-6), Lancet, Squibb Company, Princeton, NJ, USA and AstraZeneca
26. DeFronzo RA, Ratner RE, Han J, et al., Effects of exenatide 2009;374(9683):39–47. Pharmaceuticals LP, Wilmington, DE, US.
62 US ENDOCRINOLOGY
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124
Produced with Yudu - www.yudu.com